No pharmacological therapies are approved for nonalcoholic fatty liver disease (NAFLD). Luseogliflozin, a sodium glucose cotransporter 2 inhibitor, has been developed for the treatment of adults with type 2 diabetes (T2DM). The aim of this prospective, single-arm study is to evaluate the efficacy of luseogliflozin on hepatic fat content and glycated hemoglobin (HbA1c) in T2DM patients with NAFLD.
INTRODUCTION
N ON-ALCOHOLIC FATTY LIVER disease (NAFLD), including non-alcoholic steatohepatitis (NASH), is known to associate with type 2 diabetes mellitus (T2DM). [1] [2] [3] In Japan, the prevalence of T2DM is approximately 50% in patients with NAFLD, and is strongly associated with progression of fibrosis stage. 4 Advanced NASH can lead to cirrhosis and hepatocellular carcinoma. 5 Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown cardiovascular and renal protective effects in addition to glucose-lowering and body weight-lowering effects. 6, 7 Furthermore, improvement of liver tests by SGLT2 inhibitors has been reported in patients with T2DM or T2DM with NAFLD. [8] [9] [10] [11] [12] [13] However, there have been few studies of SGLT2 inhibitors for T2DM patients with NAFLD that have evaluated change in hepatic fat content by imaging.
14 Therefore, we investigated the effect of luseogliflozin on hepatic fat content evaluated by magnetic resonance imaging (MRI) in T2DM patients with NAFLD (LEAD trial).
METHODS

Subjects
W E SCREENED PATIENTS with T2DM aged older than 20 years who regularly visited the Nakakinen Clinic Medical Corporation Kenseikai (Ibaraki, Japan). Patients with T2DM and glycated hemoglobin (HbA1c) ≥6.5% and <8.5%, and NAFLD before the start of study were eligible. Non-alcoholic fatty liver disease was diagnosed based on ultrasonography. Of four known criteria (hepatorenal echo contrast, liver brightness, deep attenuation, and vascular blurring), the participants were required to have at least two findings to be given a diagnosis of NAFLD. Other exclusion criteria were: (i) patients consuming >20 g (for women) and >30 g (for men) alcohol per day; (ii) type 1 diabetes; (iii) any history of taking SGLT2 inhibitors; (iv) insulin treatment; (v) severe renal or liver disease (decompensated cirrhosis ascites, hepatic encephalopathy, and jaundice); (vi) pregnant women; (vii) patients whose treatment for T2DM was changed 8 weeks prior to baseline evaluation; (viii) those who had contraindications for MRI; (ix) patients with other chronic liver diseases (hepatitis B, hepatitis C, autoimmune hepatitis, and primary biliary cholangitis); and (x) patients with body mass index (BMI) <22 kg/m 2 . All patients provided details of their demographics, medical history, and medication usage. All patients provided written informed consent and this study was carried out in compliance with the Declaration of Helsinki and the ethical guidelines for medical and health research involving human subjects. 15 Luseogliflozin was given at 2.5 mg once daily before or after breakfast for 24 weeks. During the first 8 weeks, antihyperglycemic agents other than luseogliflozin were unchanged, except when unacceptable hyperglycemia, hypoglycemia, or adverse events (AEs) occurred.
Laboratory and clinical parameters
Venous blood samples were collected in the morning after a 12-h overnight fast. Laboratory assays included blood cell counts and measurements of serum concentrations of lactate dehydrogenase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (γGT), albumin, total cholesterol, triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol, uremic acid, fasting plasma glucose (FPG), immunoreactive insulin (IRI), C-peptide, ferritin, and type IV collagen 7 s. Hemoglobin A1c was assayed using high-performance liquid chromatography and was expressed in National Glycohemoglobin Standardization Program units. These parameters were measured with standard clinical chemistry laboratory techniques. We also evaluated a novel hepatic fibrosis marker, Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA + -M2BP). The WFA + -M2BP levels were determined with an automated immunoassay analyzer (M2BPGi, HISCL-5000; Sysmex, Kobe, Japan). 16, 17 Patients' BMI was calculated as weight in kilograms/(height in meters) 
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Quantification of hepatic fat content by MRI Hepatic fat content was evaluated as MRI hepatic fat fraction (MRI-HFF). Hepatic MRI was carried out with a 1.5-T magnet (MRT-2004, Vantage Titan; Toshiba Medical, Tokyo, Japan) equipped with a phased-array surface coil and a spine array coil. Image acquisition was undertaken in the axial plane during an end-expiratory breath-hold using a sensitivity encoding technique, to reduce the overall acquisition time to approximately 15 s. We used the two-point Dixon method, which is based on phase-shift imaging in which HFF is calculated from the signal difference between the vectors resulting from in-phase (IP) and out-of-phase (OP) signals. The two-point Dixon method for MRI is commonly used to non-invasively measure fat deposition in the liver. 22 The multi-breath-hold T1-weighted dual gradient echo sequence parameters were as follows: repetition time of 6.2 ms; echo time of 2.2 ms for OP images and 4.3 ms for IP images; flip angle, 15°; section thickness, 5 mm; matrix size, 256 × 192; and field of view, 35 cm × 38 cm. Pixel signal intensities (SI) from IP and OP images were obtained from selected regions of interest (ROIs). The SI values both in the liver and the spleen were recorded for the IP and OP images by means of 1-cm 2 circular ROIs. At three different sections (above, at the level of, and below the transverse fissure of the liver), three different ROIs were drawn (two in the right hepatic lobe and one in the left hepatic lobe), totaling nine ROIs. Selection of ROIs within the liver parenchyma was undertaken taking care to avoid areas with vessels, motion artefacts, and partial volume effects. The SI of the spleen was similarly measured and a mean SI was calculated from three ROIs selected at the corresponding liver levels. Liver fat was quantified as the percentage of relative SI loss of the liver on OP images, with the following formula: (SIin À SIout/2 × SIin) × 100, where SI is the average liver signal intensity divided by the average spleen SI, and SIin and SIout are signal intensities of IP and OP images, respectively. The SI of the spleen was used as a denominator in the formula to adjust for the lack of an objective SI scale at MRI. 23, 24 The MRI results were interpreted by an experienced radiologist who was blinded to clinical and laboratory findings.
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Study end-points
The primary end-point was the change in HbA1c and hepatic fat content from baseline. The secondary end-points were the changes in the following variables at 24 weeks: routine liver biochemistries, blood pressure, lipid profiles, and hepatic fibrosis markers. The study was approved by the institutional review board at the Nakakinen Clinic Medical Corporation Kenseikai and was registered with UMIN (UMIN000021087). All patients provided written informed consent.
Statistical analysis
Statistical analyses were carried out using an IBM SPSS version 21.0 statistical package released 2012 (IBM, Armonk, NY, USA). Data are presented as the mean ± standard deviation (SD) or percentage as appropriate. The primary and secondary end-points were analyzed using the paired t-test (Figs 1-3 , Table 2 ). Correlation coefficients were calculated by Pearson's methods (Table 3) . To identify factors affecting a decrease in hepatic fat content and HbA1c, regression analyses (stepwise variable selection method; both entry and retention criteria were set at P < 0.1) were undertaken with change in HbA1c and MRI-HFF as dependent variables and related factors as explanatory variables. P-values <0.05 were considered to be statistically significant.
RESULTS
Patient characteristics
F ORTY PATIENTS (28 men and 12 women) were enrolled in the study. Patient characteristics are described in Table 1 . One patient was removed from the study because she did not attend the clinic after study entry. The 
Changes after luseogliflozin for 24 weeks
Hepatic fat content was significantly reduced from 21.46 ± 7.17% to 15.66 ± 6.82% (P < 0.001; Fig. 1 ). The change in HbA1c from baseline to week 24, the primary end-point, was from 7.29 ± 0.65% to 7.00 ± 0.67% (P = 0.002; Table 2 ). The serial changes in HbA1c are shown in Figure 2 . Secondary end-points, AST, ALT, and γGT as hepatic function-related parameters, were also decreased after 24 weeks of treatment (Fig. 3) . In contrast, FIB4 index, NAFLD fibrosis score, type IV collagen 7S, and M2BPGi as hepatic fibrosis-related parameters were not significantly different between before and after luseogliflozin treatment, whereas serum albumin levels significantly increased after the treatment. Serum ferritin levels were significantly reduced after luseogliflozin treatment (from 120.7 ± 90.4 ng/mL to 90.1 ± 79.1 ng/mL, P < 0.001). Lipid profiles were unchanged after the treatment. The metabolic parameters including body weight and serum uric acid were significantly decreased ( Table 2) .
Correlation of changes in MRI-HFF and HbA1c with metabolic and liver function markers Table 3 shows the correlation of changes in MRI-HFF and HbA1c with those in metabolic and liver function markers. Reduction in MRI-HFF was significantly correlated with body weight, BMI, AST, ALT, TG, FPG, and serum ferritin. Change in HbA1c level was significantly correlated with body weight, BMI, LDL-C, TG, FPG, serum ferritin, M2BPGi, and MRI-HFF.
Multivariate analysis
Multivariate analysis was carried out to analyze the modulating factors of change in HbA1c and MRI-HFF. The γGT, γ-glutamyl transferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; IRI, immunoreactive insulin; LDH, lactate dehydrogenase; LDL-C, low-density lipoprotein cholesterol; M2BPGi, Mac-2 binding protein glycosylated isomer; SBP, systolic blood pressure.
results of the multiple regression analysis undertaken with change in MRI-HFF at 24 weeks as the dependent variable, and changes in each of the parameters as explanatory variables. Only the change of ALT level was selected as an independent variable associated with reduction in MRI-HFF (r = 0.1121; 95% confidence interval (CI), 0.0428-0.1814; P = 0.0023), whereas decrease in serum FPG (r = 0.0095; 95% CI, 0.0038-0.0151; P = 0.0018), TG (r = 0.0022; 95% CI, 0.0009-0.0035; P = 0.0014), and serum ferritin (r = 0.0036; 95% CI, 0.0011-0.0060; P = 0.0061) and increase in albumin (r = À1.2438; 95% CI, À1.7426 to À0.7450; P < 0.0001) were independently associated with HbA1c reduction.
Adverse events
Twenty five adverse events occurred in 16 patients. The eight AEs in six patients could not denied as associated with luseogliflozin treatment, but no liver-related adverse events were reported. Eight AEs consisted of low blood pressure (n = 3), genital itching (n = 2), constipation (n = 1), vertigo (n = 1), and dehydrosis (n = 1). There were no serious AEs.
DISCUSSION
T HIS SINGLE-ARM, PROSPECTIVE study showed the efficacy of luseogliflozin on reduction in hepatic fat content (evaluated by MRI-HFF) in T2DM patients with NAFLD and showed the improvement of several metabolic and hepatic function-related parameters. In Japan, this study is the first to confirm reduction in hepatic steatosis by MRI after treatment with SGLT2 inhibitors. For T2DM patients with/without NAFLD, serum transaminase activities have been proven to be reduced in several pilot studies. [8] [9] [10] [11] 13 Takeda et al. reported a case of T2DM with NASH-associated cirrhosis whose steatosis, inflammation, and hepatocyte ballooning was resolved after ipragliflozin treatment. 25 Akuta et al. also recently reported that canagliflozin relieved hepatic steatosis in all eight NAFLD patients, and three of them obtained improvement in liver fibrosis.
12 However, repeated liver biopsy before and after drug treatment is impractical because of invasiveness, sampling errors, interpretation variability, and cost. A randomized controlled study from Japan compared the effect of luseogliflozin with metformin in T2DM patients with NAFLD. Hepatic steatosis, evaluated by liver-to-spleen ratio on CT, was significantly reduced in the luseogliflozin group compared to the metformin group.
14 However, repeated CT also has disadvantages such as radiation exposure and insensitivity for detection of mild hepatic steatosis. In contrast, MRI has advantages such as absence of radiation exposure and high detection rate of hepatic steatosis. Magnetic resonance imaging based on the twopoint Dixon method uses a 3.5-ppm difference of fatwater chemical shift and is commonly used for In Phase (IP) and Out-of-phase (OP) acquisition. By this method, MRI-HFF in the entire liver can be easily calculated. 22, [26] [27] [28] [29] [30] This present study showed significant reduction in hepatic fat content, consistent with the results of the E-LIFT trial, 31 which were presented at the Endocrine Society's 100th annual meeting in Chicago (IL, USA). The study, funded by the Endocrine and Diabetes Foundation India in New Delhi, included 50 T2DM patients with NAFLD who were aged ≥40 years. The patients were randomly assigned to receive empagliflozin (10 mg/day) plus their standard medical treatment for T2DM, such as metformin and/or insulin, or to receive only their standard treatment without empagliflozin (control group). All patients were aware of their group assignment. At the beginning of the study and 20 weeks later, the patients had blood tests of their liver enzyme levels, which are typically elevated in NAFLD. They also underwent measurement of their liver fat using an MRI-proton density fat fraction. After 20 weeks of treatment, the liver fat of patients receiving empagliflozin decreased from an average of 16.2% to 11.3% (P < 0.0001), whereas the control group had only decreased from 16.4% to 15.6% (P = 0.057); there was a statistically significant difference between groups. In this study, serum ferritin levels, which are well known as an indicator of inflammation or severity in NAFLD, 32, 33 were significantly reduced after the treatment. It is suggested that luseogliflozin treatment can also ameliorate hepatic inflammation in NAFLD.
As the association between control of three variables (serum ALT level, body weight, and HbA1c) and NASH histological progression has been suggested, these parameters should be controlled in order to prevent NASH progression. 34, 35 The improvement of these parameters after 24 weeks of luseogliflozin treatment suggest that histological improvement can be expected in NAFLD patients with T2DM, although histological examination by repeated liver biopsies is essential to realize this hypothesis. The delta ALT level was selected as an independent variable associated with reduction in MRI-HFF. It is implicated that elevation of ALT levels in NAFLD patients can reflect degree of hepatic steatosis.
In this study, luseogliflozin did not significantly improve hepatic fibrosis markers. In an animal model of NASH, amelioration of hepatic fibrosis was observed. 36 Baseline levels in hepatic fibrosis markers were not high at entry. Patients with NASH and advanced fibrosis should Luseogliflozin in T2DM with NAFLD 69 Hepatology Research 2019; 49: 64-71 be evaluated to examine whether luseogliflozin treatment can relieve hepatic fibrosis. Additionally, we suspect that the treatment period might be too short to obtain improvement in hepatic fibrosis. Thus, a longer term study will be essential to relieve or prevent fibrosis progression.
Luseogliflozin has two advantages over other SGLT2 inhibitors currently on the market. The safety of this agent was confirmed in 13 patients with mild or moderate hepatic impairment. 37 Geometric mean ratios of maximum plasma concentration and area under the plasma concentration-time curves from time zero to infinity of unchanged luseogliflozin were 1.02 (90% CI, 0.790-1.32) and 0.774 (90% CI, 0.580-1.03), respectively, on comparing patients with hepatic impairment with healthy subjects, and 0.939 (90% CI, 0.752-1.17) and 1.00 (90% CI, 0.780-1.28), respectively, in subjects with mild and moderate hepatic impairment. 37 In addition, in a subanalysis of a double-blind placebo-controlled trial of luseogliflozin for the treatment of T2DM, serum transaminase activities in SGLT2 inhibitor-treated patients were significantly reduced compared to those in the placebo group. 38 The limitations of the study were the small sample size, short-term treatment period, and lack of control group. However, our prospective study suggests the potential benefit and safety of treatment with SGLT2 inhibitor in T2DM and NAFLD patients. A longer term, larger scale study is warranted.
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